Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial

2012/05/27 by Isabel Leroux‐Roels, Isabel Leroux-Roels, Sheron Forgus +12 · 25 citations
Medicine · Immunology and Microbiology · #Tuberculosis Research and Epidemiology #Immune responses and vaccinations #Immunodeficiency and Autoimmune Disorders

paper · doi:10.1016/j.vaccine.2012.05.035

Cited by

• Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. [europepmc]
• A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. [europepmc]
• Vaccines for the 21st century. [europepmc]
• Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. [europepmc]
• The contribution of non-human primate models to the development of human vaccines. [europepmc]
• Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells. [europepmc]
• Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. [europepmc]
• Vaccine Potentiation by Combination Adjuvants. [europepmc]
• The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans. [europepmc]
• Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates. [europepmc]
• Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial. [europepmc]
• Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. [europepmc]
• Polyfunctional CD4 + T Cells As Targets for Tuberculosis Vaccination. [europepmc]
• Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. [europepmc]
• The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. [europepmc]
• Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. [europepmc]
• Correlates of GLA family adjuvants' activities. [europepmc]
• Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review. [europepmc]
• Targeting innate immunity for tuberculosis vaccination. [europepmc]
• Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. [europepmc]
• Tuberculosis vaccine development: from classic to clinical candidates. [europepmc]
• Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology. [europepmc]
• Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants. [europepmc]
• It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity. [europepmc]
• An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. [europepmc]